Boston De Novo Design
|
Regine Bohacek, PhD |
|||||||||||||||||||||||||
|
Drug design, docking using x-ray structure of target Software: QXP/FLO+ Molecular Modeling Software McMartin, C., Bohacek, R. J. (1997) QXP: Powerful, rapid computer algorithms for structure-based drug design. Computer-Aided Mol. Design 11: 333-344. Examples Goal: discovery of potent inhibitors of neutro endopeptidase (NEP) for treatment of hypertension Company: Novartis Protein: thermolysin (model for NEP) Ksander, G. M.; de Jesus, R.; Yuan, A.; Ghai, R. D.; Trapani, A.; McMartin C.; Bohacek, R. (1997) Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. J.Med.Chem. 40(4): 495-505. Bohacek, R., De Lombaert, S., McMartin, C., Priestle, J., Grutter, M. (1996) Three-dimensional models of ACE and NEP Inhibitors and their use in the design of potent dual ACE/NEP inhibitors. JACS: 118(35): 8231-8249. (add picture) MacPherson (add picture) Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor *********************************************************** goal: discovery of potent inhibitors of cathepsin B for treatment of arthritis company: Novartis protein:cathepsin B
Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of Cathepsin B through Structure-Based Drug Design *********************************************************** goal: discovery of potent inhibitors of SRC-SH2 for treatment of osteoporosis company: Ariad Pharmaceuticals protein:SH2 domain of SRC kinase
Structure-based design and synthesis of a novel class of Src SH2 inhibitors. Buchanan, J.L.; Bohacek,R.S.;Luke, G.P.;Hatada,M.;Lu, X.;Dalgarno, D.C.;Narula, S.S.;Yuan,R.;Holt,D.A.;
X-ray Structure of Citrate Bound to Src SH2 Leads to a High-Affinity, Bone-Targeted Src SH2 Inhibitor Bohacek, R. S.; Dalgarno, D. C.; Hatada, M.; Jacobsen, V. A.; Lynch, B. A.; Macek, K. J.; Merry, T.; Metcalf, C. A., III; Narula, S. S.; Sawyer, T. K.; Shakespeare, W. C.; Violette, S. M.; Weigele, M.
Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity
Structure-Based Design of Novel Bicyclic Nonpeptide Inhibitors for the Src SH2 Domain Structure-Based Design and Solid-Phase Parallel Synthesis of Phosphorylated Nonpeptides to Explore Hydrophobic Binding at the Src SH2 Domain *********************************************************** goal: discovery of potent inhibitors of SRC kinase for treatment of osteoporosis company: Ariad Pharmaceuticals protein:SRC kinase (homology model) *********************************************************** goal: discovery of novel, potent inhibitor using de novo design program, GrowMol university: University of Wisconsin protein: pepstatin
Aspartic Protease Inhibitors Designed from Computer-Generated Templates Bind As Predicted
Peter Glunz and Daniel H. Rich, University of Wisconsin, unpublished data.
Design and Synthesis of Unsymmetrical Peptidyl Urea Inhibitors of Aspartic Peptidases
|
|||||||||||||||||||||||||